Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

Exclusion Criteria

• •Disease specific treatment within the previous 3 weeks including use of chemotherapy that is known to be active or may be active against multiple myeloma
• •Previous treatment with 17-AAG, DMAG, or other known Hsp90 inhibitor
• •Participation in any investigational drug study within 3 weeks preceding start of treatment for conventional small molecule therapy or 4 weeks preceding the start of treatment for biologic or vaccine therapy; concurrent radiation therapy is not permitted
• •Concomitant use of corticosteroids may not exceed prednisone 10 mg per day with the exception of pre-medication for transfusion of blood products and topical application
• •Concurrent treatment with any agent that alters CYP3A activity (unless maintained on stable dose)
• •Baseline QTc \>450
• •NYHA class 3 or 4 congestive heart failure
• •Left Bundle Branch Block
• •Mycardial infarction or active ischemic heart disease within 6 months
• •Grade 3 or greater peripheral neuropathy
• •Renal insufficiency, serum creatinine \>2x upper limit of normal (ULN)
• •Platelets \< 30,000 mm3 or refractory to transfusion and unable to be maintained \> 50,000 mm3
• •AST and / or ALT \> 2.0x ULN
• •ANC \<1,000 cells/mm3
• •Hemoglobin \< 8.0 g/dL
• •Presence of active infection or systemic use of antibiotics within 72 hours of treatment
• •WCBP who are breast feeding
• •Significant co-morbid condition or disease which in the judgment of the investigator would place the patient at undue risk or interfere with the study (e.g. cardiac disease such as acute coronary syndrome or unstable angina within 6 months, New York Heart Association (NYHA) class 2 or greater congestive heart failure (CHF), uncontrolled hypertension, arrhythmia requiring medication or mechanical control, chronic obstructive pulmonary disease (COPD), cirrhotic liver disease, or other conditions)